Neonorm.com allows online ordering and
features in-depth product information for dairy and beef farmers,
foal owners and veterinarians to help drive sales
Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal
health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and
production animals, foals, and high value horses, and Napo
Pharmaceuticals, Inc. (Napo), a human health company developing and
commercializing novel gastrointestinal prescription products from
plants used traditionally in rainforest areas, today announced
Jaguar’s launch of neonorm.com, a commercial website for Neonorm™
Foal and Neonorm™ Calf, Jaguar’s lead non-prescription
products.
Neonorm™ Foal is a natural, clinically-tested, non-drug product
designed for use as an anti-diarrheal in newborn horses. Diarrhea
is one of the most common clinical complaints in foals, especially
within the first 30 days of life. The crippling effects of
dehydration that often result from secretory diarrhea in foals can
manifest quickly, precipitate adverse health effects and lead to
death. Neonorm™ Calf has been formulated and clinically tested to
help proactively retain fluid in dairy calves and reduce the
severity of diarrhea—aiding calves in avoiding debilitating,
dangerous levels of dehydration associated with scours.
Neonorm.com allows online ordering of both Neonorm™ Foal and
Neonorm™ Calf directly from Jaguar and features in-depth product
information, customer testimonials, and FAQs to help drive sales.
The new site is a component of the integrated, multichannel
marketing initiatives Jaguar launched during the first half of 2017
in support of Jaguar’s Neonorm™ commercial strategy of connecting
directly with dairy and beef farmers, bovine veterinarians, equine
veterinarians, horse owners and other members of the equine
community in a targeted, engaging way to help build the Neonorm™
brand and drive sales—both directly and through Jaguar’s core dairy
market distributor as well as Henry Schein, Inc., Jaguar’s
exclusive distributor for Neonorm™ Foal.
Sample customer testimonials appearing on
Neonorm.com:
- “My experience was very positive. Used
Neonorm™ Foal on two different thoroughbred foals and it was
effective on both. Thanks!” - Tim Tompkins, Oak Orchard Farms
- “We saw Neonorm™ Foal advertised on an
RFD-TV show and talked with our vet about it. We bought it as an
‘in-case-we-need-it’, we feel it’s very inexpensive insurance to
have on hand!” - Mike and Teresa Thompson, MT Acres, LLC
- “We’ve used Neonorm™ Calf on close to
100 calves and it is working really well.” - Chelsea Lavoie,
Metcalf Farm
Neonorm.com also features ongoing monthly “Selfie Contests”
designed to drive engagement with existing and prospective Neonorm™
Foal and Neonorm™ Calf customers. To enter the contests, registered
site visitors upload a selfie photo of themselves with a dairy or
beef calf, or a selfie photo of themselves with their foal. Contest
winners are determined based on votes cast by other registered site
visitors for uploaded photos.
Neonorm™ is a standardized botanical extract derived from the
Croton lechleri tree that acts at the same last step in a
physiological pathway generally present in mammals. Foaling season
in the northern hemisphere generally runs from May through
September, while calf scours season in the U.S. generally runs from
March through June.
Proposed Merger
As announced March 31, 2017, Napo and Jaguar have entered a
definitive merger agreement. The proposed merger of Jaguar and Napo
remains subject to customary conditions to closing. Upon the
consummation of the merger, Jaguar’s name will be changed to Jaguar
Health, Inc., and Napo will operate as a wholly-owned subsidiary of
Jaguar, focused on human health. As previously stated, Jaguar and
Napo expect the merger to close by the end of July 2017.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the
development and commercialization of proprietary pharmaceuticals
for the global marketplace in collaboration with local
partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused
on developing and commercializing first-in-class gastrointestinal
products for companion and production animals, foals, and high
value horses. Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea
in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™
Foal are Jaguar’s lead non-prescription products. Neonorm™ is a
standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct products that act at the
same last step in a physiological pathway generally present in
mammals. Jaguar has nine active investigational new animal drug
applications, or INADs, filed with the FDA and intends to develop
species-specific formulations of Neonorm™ in six additional target
species, formulations of Equilevia™ in horses, and Canalevia™ for
cats and dogs.
For more information about Jaguar, please visit
www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
the proposed merger between Jaguar and Napo, the expectation that
the proposed merger will close by the end of July 2017, Jaguar’s
intention to develop species-specific formulations of Neonorm™ in
additional target species, and Jaguar’s plan to develop
formulations of Canalevia™ for cats, horses and dogs. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based
these forward-looking statements largely on its current
expectations and projections about future events. These
forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances
or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170607005723/en/
Jaguar Animal HealthPeter Hodge,
203-539-0423phodge@jaguaranimalhealth.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Sep 2023 to Sep 2024